arrow
X

Xiaolong Yan

Air Force Medical University
H指数:45
被引数:5,508

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

一线Aumolertinib (EGFR酪氨酸激酶抑制剂) 联合阿帕替尼 (VEGFR抑制剂) 与aumolertinib在EGFR突变的非小细胞肺癌患者中的比较: 一项随机,多中心,II期试验

2026-02-020
OAAI
Surficial amidogen 3D-printed poly-ether-ether-ketone (PEEK) implant promotes incision healing after chest wall reconstruction: a technical note

表面氨基3D打印聚醚醚酮(PEEK)植入物促进胸壁重建术后切口愈合:一项技术说明

2026-01-010
PRE
Lymph Node Dissection in Neoadjuvant Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-world Study

新辅助化疗免疫疗法治疗局部晚期食管鳞状细胞癌中的淋巴结清扫术:一项多中心真实世界研究

2025-12-080
PRE
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study

比较围手术期tiselizumab和pembrolizumab联合新辅助化疗在可切除非小细胞肺癌中的疗效和手术相关安全性:一项回顾性队列研究

2025-11-300
PRE
Comparison of the short-term efficacy and safety of surgical operation of neoadjuvant sintilimab and camrelizumab, both in combination with chemotherapy in the treatment of resectable non-small cell lung cancer: a single-center retrospective cohort study

比较新辅助信迪利单抗和卡瑞利珠单抗联合化疗治疗可切除非小细胞肺癌的手术疗效及安全性短期比较:一项单中心回顾性队列研究

2025-09-300
PRE
Physiological and psychological symptom management based on electronic patient-reported outcomes: the TD-WELLBEING randomized clinical trial

基于电子患者报告结局的生理与心理症状管理:TD-WELLBEING 随机临床试验

2025-08-070
OAAI
Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma

新辅助化放疗与化免疫疗法治疗食管鳞状细胞癌

2025-05-012
PRE